與眼科護理專業人員攜手合作，推動視力護理發展†1，照顧每一雙眼睛。2,3
我們致力支持眼科護理機構的業務發展，並透過高品質的隱形眼鏡產品，協助滿足不同患者的多元視力矯正需求。2,3
全球接近 4,300 萬名隱形眼鏡佩戴者選用 CooperVision® 隱形眼鏡。‡3
CooperVision是全球 No.1 軟性隱形眼鏡製造商，提供最廣泛的軟性隱形眼鏡處方選擇§4
CooperVision® 隱形眼鏡產品組合可滿足 99.96% 患者的視力矯正需求。2,3
為何選擇 CooperVision®
致力推動近視管理發展
CooperVision 是近視管理領域的全球領導者，致力與眼科護理專業人員攜手合作，透過具實證支持5-13的近視管理方案，協助近視兒童邁向更佳的終身視力健康。*◊¶6,7
*Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
†Combination of 2022 market research based on global volume data and internal estimates.
‡Based on internal estimates for rolling 12 month sales data, as of October 2024. Includes 1 Day disposable, 2 weekly replacement, monthly replacement disposable contact lenses and specialty lens designs including Ortho-k and sclerals.
§Based on Rx option combinations (sphere, cylinder, axis & add) manufactured, across all soft lenses in sphere, toric & multifocal, in SiHy and hydrogel from 4 main manufacturers. Includes 1 Day, 2 weekly, and monthly disposable contact lenses. Cosmetic & Photochromatic contact lenses not included. Multiple base curve variants not included.
◊MiSight® 1 day, designed for myopia control, shows sustained slowing of eye growth over time on average. While eyes are still growing; children fit ages 8-12 and followed for 6-years. n=40.
¶Compared to a single vision 1-day lens.
**Refers to continuous manufacturing improvement processes undertaken by CooperVision to reduce its Scope 1 and 2 carbon emissions.
††Carbon footprint is limited to Scope 1 and 2 emissions, defined as: Scope 1 emissions are direct emissions from owned or controlled sources. Scope 2 emissions are indirect emissions from the generation of purchased energy.
‡‡CooperVision's 2022 Environmental, Social, and Governance Report.
References:
1. CVI data on file, 2023.
2. CVI data on file, 2021. Rx coverage database n=101,973 aged 14 to 70 years.
3. CVI data on file, 2026.
4. CVI data on file, 2026. Industry reports and internal estimates based on Tyler's Quarterly, 06/2025 and competitor websites.
5. Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. OVS 2019; 96(8):556-567.
6. Chamberlain P, et al. Long-term Effect of Dual-focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. OVS 2022 Mar 1;99(3):204-212.
7. Chamberlain P, Arumugam B, et al. Myopia progression on cessation of Dual-Focus contact lens wear: MiSight 1 day 7 year findings. OVS 2025 In Press;98:E-abstract 210049.
8. Woods J et al. Ocular health of children wearing daily disposable contact lenses over a 6-year period. CLAE 2021 Aug;44(4):101391.
9. Sulley A et al. Experience and subjective responses for children switched from single vision to dual focus myopia control daily disposable contact lenses. BCLA paper presentation 2021.
10. Jakobsen, Møller. Control of myopia using orthokeratology lenses in Scandinavian children aged 6 to 12 years. Eighteen-month data from the Danish Randomized Study: Clinical study Of Near-sightedness; Treatment with Orthokeratology Lenses (CONTROL study). Acta Ophthalmol. 2022 Mar;100(2):175-182.
11. Lu et al. Efficacy of Trial Fitting and Software Fitting for Orthokeratology Lens: One-Year Follow-Up Study. Eye Contact Lens. 2018 Sep;44(5):339-343.
12. Rappon et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomized controlled, efficacy and safety study (CYPRESS) British Journal of Ophthalmology Published Online First: 01 September 2022.
13. Laughton et al. Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years. 2022 American Academy of Optometry annual meeting.
20291 09/26